GlassScriptPhysician profile
Mozhgan Alijani
NPI 1194209015
$1,098.79
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $43.89 · 2021: $87.13 · 2022: $135 · 2023: $486 · 2024: $49.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $449 · Food and Beverage: $86.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $449.00 |
| Food and Beverage | $86.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $449.00 | 2023 | |
| Horizon Therapeutics Plc | $160.48 | 2019-2021 | |
| Medline Industries LP | $134.53 | 2019 | |
| Smith+Nephew, INC. | $113.18 | 2022 | |
| Biocomposites INC | $69.96 | 2019 | |
| Polynovo North America LLC | $49.59 | 2024 | Novosorb Btm |
| Sebela Pharmaceuticals INC. | $30.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.66 | 2022 | |
| Kerecis Limited | $20.86 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Nabriva Therapeutics, Plc | $17.57 | 2021 | |
| Novo Nordisk INC | $16.05 | 2023 | Rybelsus, Ozempic |
| Bioventus LLC | $15.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mozhgan Alijani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.